keyword
MENU ▼
Read by QxMD icon Read
search

mesenchymal stem cell systemic sclerosis

keyword
https://www.readbyqxmd.com/read/28557239/the-neuroprotective-effect-of-mesenchymal-stem-cells-on-an-experimentally-induced-model-for-multiple-sclerosis-in-mice
#1
Marwa M Mahfouz, Rania M Abdelsalam, Marwa A Masoud, Hanaa A Mansour, Omar A Ahmed-Farid, Sanaa A Kenawy
Multiple sclerosis (MS) is a chronic autoimmune demyelinating neurodegenerative central nervous system disorder. The aim of the present study was to investigate the prophylactic effect exerted by the one-time intraperitoneal injection of mesenchymal stem cells (MSCs) 1 × 10(6) and 14-day intraperitoneal injection of methylprednisolone (MP) 40 mg/kg in an experimental autoimmune encephalomyelitis (EAE). EAE was induced by intradermal injection of rat spinal cord homogenate with complete Freund's adjuvant in Swiss mice...
May 29, 2017: Journal of Biochemical and Molecular Toxicology
https://www.readbyqxmd.com/read/28355729/-an-update-of-the-application-and-mechanism-of-mesenchymal-stem-cells-for-treatment-of-systemic-sclerosis
#2
X J Song, Y Liu
No abstract text is available yet for this article.
April 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/28213588/a-differential-autophagy-dependent-response-to-dna-double-strand-breaks-in-bone-marrow-mesenchymal-stem-cells-from-sporadic-als-patients
#3
Shane Wald-Altman, Edward Pichinuk, Or Kakhlon, Miguel Weil
Amyotrophic lateral sclerosis (ALS) is an incurable motor neurodegenerative disease caused by a diversity of genetic and environmental factors that leads to neuromuscular degeneration and has pathophysiological implications in non-neural systems. Our previous work showed abnormal levels of mRNA expression for biomarker genes in non-neuronal cell samples from ALS patients. The same genes proved to be differentially expressed in the brain, spinal cord and muscle of the SOD1(G93A) ALS mouse model. These observations support the idea that there is a pathophysiological relevance for the ALS biomarkers discovered in human mesenchymal stem cells (hMSCs) isolated from bone marrow samples of ALS patients (ALS-hMSCs)...
May 1, 2017: Disease Models & Mechanisms
https://www.readbyqxmd.com/read/28186117/amelioration-of-experimental-autoimmune-encephalomyelitis-through-transplantation-of-placental-derived-mesenchymal-stem-cells
#4
Hong Jiang, Yuanyuan Zhang, Kewei Tian, Beibei Wang, Shu Han
Placental derived mesenchymal stem cells (PMSCs) have been suggested as a possible source of cells to treat multiple sclerosis (MS) due to their immunomodulatory functions, lack of ethical concerns, and potential to differentiate into neurons and oligodendrocytes. To investigate whether PMSCs share similar characteristics with embryonic mesenchymal stem cells (EMSCs), and if transplanted PMSCs have the ability to integrate and replace degenerated neural cells, we transplanted rat PMSCs and EMSCs into the central nervous system (CNS) of Lewis rats with experimental autoimmune encephalomyelitis (EAE), an animal model of MS...
February 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28173869/characteristics-of-human-adipose-derived-stem-cells-in-scleroderma-in-comparison-to-sex-and-age-matched-normal-controls-implications-for-regenerative-medicine
#5
Michelle Griffin, Caroline M Ryan, Omar Pathan, David Abraham, Christopher P Denton, Peter E M Butler
BACKGROUND: Adipose-derived stem cells (ADSCs) are emerging as an alternative stem cell source for cell-based therapies. Recent data suggest that autologous ADSC-enriched micrografting improves the effects of facial involvement in systemic sclerosis (SSc). We have extensively characterised ADSCs from SSc patients and compared their phenotype and function to healthy age- and sex-matched control ADSCs. METHODS: ADSCs were isolated and characterised from a cohort of six SSc patients (ADSC-SSc) and were compared to six healthy age- and sex-matched controls (ADSC-N)...
February 7, 2017: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/28132855/bone-marrow-derived-mesenchymal-stem-cells-expressing-thioredoxin-1-attenuate-bleomycin-induced-skin-fibrosis-and-oxidative-stress-in-scleroderma
#6
Miao Jiang, Yiwu Yu, Jingying Luo, Qingyun Gao, Lili Zhang, Qiangxiong Wang, Jingjun Zhao
Systemic sclerosis (SSc) is an autoimmune disorder that affects multiple organs. It is characterized by a thickening of the dermis and connective tissue caused by collagen accumulation, and vascular injuries that induce hypoxia. The present study investigated the therapeutic potential of bone marrow-derived mesenchymal stem cells (BMSCs) expressing thioredoxin 1 (Trx-1) in treating SSc-mediated skin disease after transplantation into a bleomycin-induced murine model. Mice with bleomycin-induced SSc were subcutaneously injected with BMSCs or Trx-1-overexpressing BMSCs and exposed to hypoxic conditions for 48 hours...
January 26, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28132681/human-mesenchymal-stem-cells-genetically-engineered-to-overexpress-brain-derived-neurotrophic-factor-improve-outcomes-in-huntington-s-disease-mouse-models
#7
Kari Pollock, Heather Dahlenburg, Haley Nelson, Kyle D Fink, Whitney Cary, Kyle Hendrix, Geralyn Annett, Audrey Torrest, Peter Deng, Joshua Gutierrez, Catherine Nacey, Karen Pepper, Stefanos Kalomoiris, Johnathon D Anderson, Jeannine McGee, William Gruenloh, Brian Fury, Gerhard Bauer, Alexandria Duffy, Theresa Tempkin, Vicki Wheelock, Jan A Nolta
Huntington's disease (HD) is a fatal degenerative autosomal dominant neuropsychiatric disease that causes neuronal death and is characterized by progressive striatal and then widespread brain atrophy. Brain-derived neurotrophic factor (BDNF) is a lead candidate for the treatment of HD, as it has been shown to prevent cell death and to stimulate the growth and migration of new neurons in the brain in transgenic mouse models. BDNF levels are reduced in HD postmortem human brain. Previous studies have shown efficacy of mesenchymal stem/stromal cells (MSC)/BDNF using murine MSCs, and the present study used human MSCs to advance the therapeutic potential of the MSC/BDNF platform for clinical application...
May 2016: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/28106077/mesenchymal-stem-cell-transplantation-in-tight-skin-mice-identifies-mir-151-5p-as-a-therapeutic-target-for-systemic-sclerosis
#8
Chider Chen, Dandan Wang, Alireza Moshaverinia, Dawei Liu, Xiaoxing Kou, Wenjing Yu, Ruili Yang, Lingyun Sun, Songtao Shi
Systemic sclerosis (SSc), an autoimmune disease, may cause significant osteopenia due to activation of the IL4Rα/mTOR pathway. Mesenchymal stem cell transplantation (MSCT) can ameliorate immune disorders in SSc via inducing immune tolerance. However, it is unknown whether MSCT rescues osteopenia phenotype in SSc. Here we show that MSCT can effectively ameliorate osteopenia in SSc mice by rescuing impaired lineage differentiation of the recipient bone marrow MSCs. Mechanistically, we show that donor MSCs transfer miR-151-5p to the recipient bone marrow MSCs in SSc mice to inhibit IL4Rα expression, thus downregulating mTOR pathway activation to enhance osteogenic differentiation and reduce adipogenic differentiation...
April 2017: Cell Research
https://www.readbyqxmd.com/read/28096400/defining-recovery-neurobiology-of-injured-spinal-cord-by-synthetic-matrix-assisted-hmsc-implantation
#9
Alexander E Ropper, Devang K Thakor, InBo Han, Dou Yu, Xiang Zeng, Jamie E Anderson, Zaid Aljuboori, Soo-Woo Kim, Hongjun Wang, Richard L Sidman, Ross D Zafonte, Yang D Teng
Mesenchymal stromal stem cells (MSCs) isolated from adult tissues offer tangible potential for regenerative medicine, given their feasibility for autologous transplantation. MSC research shows encouraging results in experimental stroke, amyotrophic lateral sclerosis, and neurotrauma models. However, further translational progress has been hampered by poor MSC graft survival, jeopardizing cellular and molecular bases for neural repair in vivo. We have devised an adult human bone marrow MSC (hMSC) delivery formula by investigating molecular events involving hMSCs incorporated in a uniquely designed poly(lactic-co-glycolic) acid scaffold, a clinically safe polymer, following inflammatory exposures in a dorsal root ganglion organotypic coculture system...
January 31, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27882538/gene-therapy-with-mesenchymal-stem-cells-expressing-ifn-%C3%A3-ameliorates-neuroinflammation-in-experimental-models-of-multiple-sclerosis
#10
C Marin-Bañasco, K Benabdellah, C Melero-Jerez, B Oliver, M J Pinto-Medel, I Hurtado-Guerrero, F de Castro, D Clemente, O Fernández, F Martin, L Leyva, M Suardíaz
BACKGROUND AND PURPOSE: Recombinant IFN-ß is one of the first-line treatments in multiple sclerosis (MS), despite its lack of efficacy in some patients. In this context, mesenchymal stem cells (MSCs) represent a promising therapeutic alternative due to their immunomodulatory properties and multipotency. Moreover, by taking advantage of their pathotropism, these cells can be genetically modified to be used as carriers for delivering or secreting therapeutic drugs into injured tissues...
February 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/27714895/gingival-stromal-cells-as-an-in-vitro-model-cannabidiol-modulates-genes-linked-with-amyotrophic-lateral-sclerosis
#11
Thangavelu Soundara Rajan, Domenico Scionti, Francesca Diomede, Gianpaolo Grassi, Federica Pollastro, Adriano Piattelli, Lucio Cocco, Placido Bramanti, Emanuela Mazzon, Oriana Trubiani
Research in recent years has extensively investigated the therapeutic efficacy of mesenchymal stromal cells in regenerative medicine for many neurodegenerative diseases at preclinical and clinical stages. However, the success rate of stem cell therapy remains less at translational phase. Lack of relevant animal models that potentially simulate the molecular etiology of human pathological symptoms might be a reason behind such poor clinical outcomes associated with stem cell therapy. Apparently, self-renewal and differentiation ability of mesenchymal stem cells may help to study the early developmental signaling pathways connected with the diseases, such as Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), etc...
October 7, 2016: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/27679683/immunomodulation-by-mesenchymal-stem-cells-interplay-between-mesenchymal-stem-cells-and-regulatory-lymphocytes
#12
EDITORIAL
Oscar Ka-Fai Ma, Koon Ho Chan
Mesenchymal stem cells (MSCs) possess immunomodulatory properties, which confer enormous potential for clinical application. Considerable evidence revealed their efficacy on various animal models of autoimmune diseases, such as multiple sclerosis, systemic lupus erythematosus and uveitis. MSCs elicit their immunomodulatory effects by inhibiting lymphocyte activation and proliferation, forbidding the secretion of proinflammatory cytokines, limiting the function of antigen presenting cells, and inducing regulatory T (Treg) and B (Breg) cells...
September 26, 2016: World Journal of Stem Cells
https://www.readbyqxmd.com/read/27515308/identification-and-validation-of-multiple-cell-surface-markers-of-clinical-grade-adipose-derived-mesenchymal-stromal-cells-as-novel-release-criteria-for-good-manufacturing-practice-compliant-production
#13
Emily T Camilleri, Michael P Gustafson, Amel Dudakovic, Scott M Riester, Catalina Galeano Garces, Christopher R Paradise, Hideki Takai, Marcel Karperien, Simon Cool, Hee-Jeong Im Sampen, A Noelle Larson, Wenchun Qu, Jay Smith, Allan B Dietz, Andre J van Wijnen
BACKGROUND: Clinical translation of mesenchymal stromal cells (MSCs) necessitates basic characterization of the cell product since variability in biological source and processing of MSCs may impact therapeutic outcomes. Although expression of classical cell surface markers (e.g., CD90, CD73, CD105, and CD44) is used to define MSCs, identification of functionally relevant cell surface markers would provide more robust release criteria and options for quality control. In addition, cell surface expression may distinguish between MSCs from different sources, including bone marrow-derived MSCs and clinical-grade adipose-derived MSCs (AMSCs) grown in human platelet lysate (hPL)...
August 11, 2016: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/27426933/autologous-mesenchymal-stromal-cells-as-a-therapeutic-in-als-and-epilepsy-patients-treatment-modalities-and-ex-vivo-neural-differentiation
#14
REVIEW
Antos Shakhbazau, Michael Potapnev
Stem cell therapy for incurable central nervous system disorders has long been viewed as a promising therapeutic option. In this review, we discuss the existing data and approaches on cell transplantation in the context of the neural differentiation potential of adult autologous stem cells, focusing on those of mesenchymal origin as easily accessible and well studied. Mesenchymal stromal cells (MSCs) are a heterogeneous cell population with a remarkable therapeutic plasticity, demonstrated by their ability to dampen inflammation, inhibit pathogenic immune responses and secrete neuroprotective factors...
October 2016: Cytotherapy
https://www.readbyqxmd.com/read/27335539/clinical-trial-perspective-for-adult-and-juvenile-huntington-s-disease-using-genetically-engineered-mesenchymal-stem-cells
#15
REVIEW
Peter Deng, Audrey Torrest, Kari Pollock, Heather Dahlenburg, Geralyn Annett, Jan A Nolta, Kyle D Fink
Progress to date from our group and others indicate that using genetically-engineered mesenchymal stem cells (MSC) to secrete brain-derived neurotrophic factor (BDNF) supports our plan to submit an Investigational New Drug application to the Food and Drug Administration for the future planned Phase 1 safety and tolerability trial of MSC/BDNF in patients with Huntington's disease (HD). There are also potential applications of this approach beyond HD. Our biological delivery system for BDNF sets the precedent for adult stem cell therapy in the brain and could potentially be modified for other neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Alzheimer's disease, and some forms of Parkinson's disease...
May 2016: Neural Regeneration Research
https://www.readbyqxmd.com/read/27256975/stem-cell-transplantation-and-mesenchymal-cells-to-treat-autoimmune-diseases
#16
Alan Tyndall, Jacob M van Laar
Since the start of the international stem cell transplantation project in 1997, over 2000 patients have received a haematopoietic stem cell transplant (HSCT), mostly autologous, as treatment for a severe autoimmune disease, the majority being multiple sclerosis (MS), systemic sclerosis (SSc) and Crohn's disease. There was an overall 85% 5-year survival and 43% progression-free survival. Around 30% of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution...
June 2016: La Presse Médicale
https://www.readbyqxmd.com/read/27252423/perivascular-cells-in-diffuse-cutaneous-systemic-sclerosis-overexpress-activated-adam12-and-are-involved-in-myofibroblast-transdifferentiation-and-development-of-fibrosis
#17
Paola Cipriani, Paola Di Benedetto, Piero Ruscitti, Vasiliki Liakouli, Onorina Berardicurti, Francesco Carubbi, Francesco Ciccia, Giuliana Guggino, Francesca Zazzeroni, Edoardo Alesse, Giovanni Triolo, Roberto Giacomelli
OBJECTIVE: Microvascular damage is pivotal in the pathogenesis of systemic sclerosis (SSc), preceding fibrosis, and whose trigger is not still fully understood. Perivascular progenitor cells, with profibrotic activity and function, are identified by the expression of the isoform 12 of ADAM (ADAM12) and this molecule may be upregulated by transforming growth factor-β (TGF-β). The goal of this work was to evaluate whether pericytes in the skin of patients with diffuse cutaneous SSc (dcSSc) expressed ADAM12, suggesting their potential contribution to the fibrotic process, and whether TGF-β might modulate this molecule...
July 2016: Journal of Rheumatology
https://www.readbyqxmd.com/read/27250994/mesenchymal-stromal-stem-cells-do-not-ameliorate-experimental-autoimmune-encephalomyelitis-and-are-not-detectable-in-the-central-nervous-system-of-transplanted-mice
#18
Pierre Abramowski, Susanne Krasemann, Thomas Ernst, Claudia Lange, Harald Ittrich, Michaela Schweizer, Axel R Zander, Roland Martin, Boris Fehse
Mesenchymal stromal/stem cells (MSCs) constitute progenitor cells that can be isolated from different tissues. Based on their immunomodulatory and neuroprotective functions, MSC-based cell-therapy approaches have been suggested to antagonize inflammatory activity and neuronal damage associated with autoimmune disease of the central nervous system (CNS), for example, multiple sclerosis (MS). Intravenous MSC transplantation was reported to ameliorate experimental autoimmune encephalomyelitis (EAE), the murine model of MS, within days after transplantation...
August 1, 2016: Stem Cells and Development
https://www.readbyqxmd.com/read/27207172/adipose-derived-mesenchymal-stem-cells-in-autoimmune-disorders-state-of-the-art-and-perspectives-for-systemic-sclerosis
#19
REVIEW
Alexandre T J Maria, Marie Maumus, Alain Le Quellec, Christian Jorgensen, Danièle Noël, Philippe Guilpain
Mesenchymal stromal/stem cells (MSC) are non-hematopoietic multipotent progenitor cells, first described in bone marrow in the middle of last century. Since then, MSC have been the objects of a myriad of publications, progressively increasing our knowledge on their potentialities and bringing high expectancies for their regenerative properties. During the same period, numerous tissues, such as adipose tissue, placenta, or umbilical cord, have been used as alternative sources of MSC in comparison with bone marrow...
April 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/27158466/update-on-the-pathogenesis-of-scleroderma-focus-on-circulating-progenitor-cells
#20
REVIEW
Alexandra Maria Giovanna Brunasso, Cesare Massone
In systemic sclerosis (SSc), the development of fibrosis seems to be a consequence of the initial ischemic process related to an endothelial injury. The initial trigger event in SSc is still unknown, but circulating progenitor cells (CPCs) might play a key role. Such cells have the ability to traffic into injury sites, exhibiting inflammatory features of macrophages, tissue remodeling properties of fibroblasts, and vasculogenesis functions of endothelial cells. The different subsets of CPCs described thus far in SSc arise from a pool of circulating monocyte precursors (CD14 (+) cells) and probably correspond to a different degree of differentiation of a single cell of origin...
2016: F1000Research
keyword
keyword
113794
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"